Keyphrases
Mutant p53
46%
Wild-type p53
35%
Leucine-rich Repeat Kinase 2 (LRRK2)
32%
Small Molecules
30%
Murine Double Minute 2 (MDM2)
24%
MDM2-p53 Interaction
24%
P53 Protein
18%
Yeast Assay
18%
Parkinson's Disease
17%
Tumor Cells
16%
Bisphosphonates
16%
DNA-binding Domain
16%
New Inhibitors
16%
Tagless
16%
Clinical Samples
16%
Lysosome
16%
Cancer Treatment
15%
Growth Inhibition
15%
Chalcone
14%
Tumor
13%
Antitumor Activity
13%
R1441C
12%
P53 DNA Binding
12%
TAp73
12%
P53 Transcriptional Activity
11%
VPS35
11%
Phosphorylation
10%
Mutation Carriers
10%
DNA Binding
10%
Potential Inhibitors
10%
Rab10
9%
Activation Status
9%
Kinase Cascade
9%
Human Tumor Cells
9%
TP53 mutation
8%
Peripheral Blood
8%
Peripheral Blood Neutrophils
8%
Human Cancer
8%
P53 Transactivation
8%
Idiopathic Parkinson's Disease
8%
Actin
8%
Human Peripheral Blood Monocytes
8%
MDM2-p53
8%
Astragalus
8%
Saponin Fraction
8%
Multiple Hotspots
8%
Small Molecule Targeting
8%
Prenylated Chalcone
8%
Cell Modulation
8%
Gambogic Acid
8%
Biochemistry, Genetics and Molecular Biology
P53
80%
Small Molecule
25%
Anticancer
25%
Wild Type
23%
Kinase
19%
Phosphotransferase
19%
Leucine-Rich Repeat
16%
LRRK2
16%
Lysosome
16%
DNA-binding Domain
10%
VPS35
10%
Protein Family
9%
Cell Death
9%
DNA Binding
9%
Isoform
9%
Crystal Structure
8%
Family Interaction
8%
Hsp70
8%
Protein Kinase C
8%
Phospholipid
8%
Ceramide
8%
Antibody Affinity
8%
Growth Inhibition
5%
Pharmacology, Toxicology and Pharmaceutical Science
Protein P53
100%
Neoplasm
37%
Malignant Neoplasm
19%
Chalcone
16%
Antitumor Activity
10%
Chalcone Derivative
10%
Cytotoxicity
10%
Astragalus
8%
Liver Cell Carcinoma
8%
Leucine Rich Repeat Kinase 2
8%
Gambogic Acid
8%
Neuroblastoma
8%
Saponin
8%
Xanthone Derivative
5%
